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ABSTRACT
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a recurrent and
progressive disease that causes proximal, symmetrical extremity weakness. The disease
is diagnosed using clinical features, electrophysiologic testing, albumino-cytological
disassociation in the cerebrospinal fluid, and sural nerve plexus biopsy. However,
because of the low sensitivity of diagnostic criteria and other similar neuropathies,
including diabetic polyneuropathy (DPN), accurate diagnosis is difficult. Differentiating
between these diseases is especially important as CIDP’s changes are reversible and
DPN’s are not. Making this differentiation allows for symptomatic improvement in
a patient’s quality of life that would not be achieved otherwise. Early recognition
and treatment with modalities including corticosteroids, plasmapheresis, and IVIG,
demonstrate improvement in a majority of patients. Primary care physicians (PCP)
encounter patients with diabetes daily. It is important for PCPs to have a level of
familiarity with CIDP to best care for those patients.
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INTRODUCTION
In 1958, JH Austin identified a cohort of patients
suffering from a recurrent, but steroid-responsive,
polyneuropathy.1 This was officially named chronic
inflammatory demyelinating polyneuropathy (CIDP)
in 1975 by Peter Dyck.2 CIDP is the most common
chronic inflammatory neuropathy affecting the
peripheral nervous system3 and the most common
treatable autoimmune neuropathy, accounting
for 10% of patients referred to neurology clinics.4-6
Prevalent in 1-9 cases per 100,000 individuals, it tends
to occur in adults between 40-60 years old5,7 and
affects males 58-66% of the time.3,4-7
The disease can be seen in both humans and
other mammals.4 It is characterized by progressive,
primarily proximal, symmetrical extremity weakness,
without muscle wasting.1,2,4-10 Like the motor defects,
the associated sensory dysfunctions are non-length
dependent neuropathies that result in numbness,
paresthesia (described as a tingling or buzzing
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sensation), and proprioception issues.5-7 Neuropathic
pain is rare and autonomic dysfunction is mild
with symptoms usually confined to the bowel and
bladder if present at all.5,7,8 Symptoms are routinely
progressive but one third can have a relapsing
and remitting phenotype with the peak severity of
symptoms at eight weeks.1-3,5-10 Despite criteria from
the American Academy of Neurology and European
Federation of Neurology Society/Peripheral Nerve
Society, diagnosis is difficult owing to their low
sensitivities.3 These criteria depend upon clinical
features, electrophysiologic testing, albuminocytological disassociation in the cerebrospinal fluid
(CSF), sural nerve plexus biopsy and MRI.6,8 Atypical
forms of CIDP further compound this diagnostic
dilemma, with many patients carrying the diagnosis
without fulfilling the criteria.1,7,11 Diagnostic certainty
is complicated by CIDP mimics (Table #1) and other
common concomitant neurologic conditions like
diabetic polyneuropathy (DPN). Familiarity with the
pathology and clinical course of CIDP is important
for primary care physicians (PCPs) to make the
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TABLE #1: Symptom comparison of different demyelinating polyneuropathies.

correct diagnosis and ensure rapid and appropriate
treatment.
CASE PRESENTATION
A 49-year-old male with chronic low back pain and a
seven-year history of diabetic peripheral neuropathy
resulting from twenty years of poorly controlled
type 2 diabetes, presented to his PCP complaining
of a two-week history of worsening pain and
weakness. Prior to this, the patient had complaints
of progressive neuropathic pain and failed multiple
trials of medications, including opiates. Ultimately,
he had a spinal cord stimulator implanted. The
patient reported “lightning [shooting] down both
legs” causing weakness with weight-bearing as well
as falls. Following the appointment with his PCP, the
patient was immediately sent to pain management
for the evaluation of the stimulator. CT imaging
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of the lumbar and thoracic spine was ordered at
the request of the pain management specialist.
This revealed no acute changes and appropriate
placement of the spinal cord stimulator. Neurology
was consulted and ordered an electromyogram and
nerve conduction study of the lower extremities. The
initial impression was severe diabetic neuropathy.
The neurologist referred the patient to a colleague
and repeat electrophysiologic testing at six weeks
following the initial presentation showed ‘very
severe chronic axonal sensory-motor neuropathy’
and further testing was recommended of the
upper extremities, which demonstrated a
demyelinating neuropathy. Evaluation by neurology
included thyroid levels, RPR, vitamin B12, copper,
ganglioside antibodies and serum electrophoresis,
which returned as normal. Sedimentation rate,
homocysteine, methyl-malonic acid, and free Kappa/
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Lambda light chains were elevated, while vitamin B6
and zinc levels were low. A normal opening pressure
of 33 mmHg on lumbar puncture was obtained.
Red and white blood cells were normal within the
cerebrospinal fluid (CSF), and both glucose (90
mg/dL) and protein (55 mg/dL) were elevated.
Electrophysiologic testing of the bilateral upper
extremities was consistent with CIDP (Figures #1 &
#2).
His chronic kidney disease and poorly controlled
diabetes limited the use of IVIG and high-dose

steroids. Therefore, he began treatment with five
inpatient sessions of plasma exchange (PLEX) and
physical therapy. Within two weeks, increased
lower extremity strength, decreased pain, and
unassisted ambulation was noted. One month after
the initial treatment, he received a second course
of five PLEX treatments. By six-weeks following the
second treatment, the patient noted continued
improvement in symptoms with decreased pain and
increased range of motion. This lasted three months.
A functional decline in strength and an increase in
limb paresthesias necessitated a third round of PLEX

FIGURE 1: Nerve Conduction Study - Motor (left column) and F-Wave (right column) complexes for bilateral
median nerves. The motor nerve conduction (MNC) of bilateral median nerves was tested using the abductor
pollicis brevis (APB). Amplitude is related to the number of axons in a nerve, therefore a reduction in amplitude
indicates a loss of neurons. Latency is a marker of time and when prolonged, signifies a demyelinating process.
Conduction velocity, a measure of speed, is affected by both axonal loss and demyelination. F waves evaluate
proximal demyelination by looking at conduction speeds. F waves are created when a stimulus is applied to a
distal motor nerve. The impulse travels antidromically from peripheral nerve to anterior horn cell and is bounced
back down the motor neuron to create muscle contraction. In early disease course, F waves may be normal. In
mid-course of disease, F waves will show delayed latency. In late/severe disease, F waves may be absent. In our
patient, the left median motor amplitude was reduced with a prolonged distal motor latency and a moderately
slow conduction velocity in the demyelinating range. The left median F wave latency was very prolonged, indicating proximal demyelination. The right median motor amplitude was moderately reduced, with a prolonged
distal motor latency and very slowed conduction velocity registering in the demyelinating range. The right
median F wave latency was normal.
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FIGURE 2: Nerve Conduction Study - Motor (left column) and F-Wave (right column) complexes for bilateral ulnar nerves. The motor nerve conduction (MNC) of bilateral ulnar nerves was tested using the abductor
digiti minimi (ADM). The left ulnar motor amplitude was very reduced with a prolonged distal motor latency
and moderately slow conduction velocities indicating demyelination and loss of axons. The left ulnar F wave
response was absent indicating late/severe disease progression. The right ulnar motor amplitude demonstrated
a conduction block at the elbow, with prolonged distal motor latency and slowed conduction velocities in the
demyelinating range. A conduction block occurs when the loss of myelin thickness is great enough to lead to
saltatory conduction failure and severely prolonged motor latencies and conduction velocity. The right ulnar F
wave latency was also prolonged.

treatments. The patient improved, but not to his
previous level of functioning, and left the hospital
requiring a walker to ambulate. One month later,
the patient passed away suddenly at home from a
hypoxic episode.
DISCUSSION
CIDP Pathophysiology and Diagnosis
CIDP is classified as a demyelinating process of
the peripheral nervous system.2,4-6,10,13 The precise
pathological mechanisms are still largely unknown
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despite treatment based studies rendering genetic,
metabolic, and toxic causes unlikely.12 Cell-mediated
and humoral immune-mediated inflammation
directed against the peripheral nerve epitopes of
myelin sheath Schwann Cells are implicated for
this polyradiculoneuropathy.1,3,3 Cell-mediated and
humoral influenced T cells affect the permeability
of the blood-nerve barrier, allowing antibodies
to attack the endoneurium.6 The Schwann cells
begin to react to this damage and lay down a new
myelin sheath. This demyelinating-remyelinating
picture primarily targets proximal peripheral nerves,
specifically spinal roots, proximal nerve trunks, and
major plexuses.2,4-6,12,13
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Despite only 50%-60% of patients with CIDP fulfilling
one of the over fifteen established criteria,2,5,7
components of these criteria do have merit and
can help aid the physician in early diagnosis. One
such component is electrophysiologic testing (Table
#2), which demonstrates primary demyelination
by reduced conduction velocities, prolonged
distal motor latencies, prolonged F wave latencies,
and a patchy temporal dispersion, or conduction
blockade.2,4-6,13 Secondly, CSF studies reveal an
albumin-cytologic disassociation, with increased
protein levels from damage to the blood-CSF barrier
at proximal nerve roots.5,6,10,14 To further emphasize

the inflammatory nature of CIDP, fibrinogen,
haptoglobin and prealbumin, all indicators of chronic
and acute inflammation, are seen in the CSF.14 Finally,
a nerve biopsy of affected proximal sensory nerves
is diagnostic but should be saved for last resort.5,6,12,13
Microscopic evaluation of biopsies from patients
show macrophage associated demyelinationremyelination, endoneurial infiltrates of CD8+ and
CD4+ T cells, hypermyelination formation of ‘onion
bulbs’, axonal degeneration, edema, and deposition
of complement and immunoglobulin.2,4-6,12,13

TABLE #2: EMG comparison of different demyelinating polyneuropathies. LLN = lower limit normal;
ULN = upper limit normal. Conduction Velocities = Segment Distance (mm) per change of Segment
Latency (msec). Distal Motor Latencies (msec) = the time from stimulus to the distal motor
response is recorded. Distal motor nerves have tortuous routes. H Wave: the electrical equivalent
of the monosynaptic stretch reflex. Stimulate 1a fibers to dorsal root ganglion to anterior horn cells
to alpha motor axon to muscle. F Wave: long latency muscle action potential seen after maximal
stimulation to a nerve. Stimulus travels through motor fibers to anterior horn cells, depolarized
at critical time, to alpha motor axon to small late motor/muscle response. Seen AFTER the direct
motor response. Used to test proximal nerve abnormalities. Temporal Dispersion = Seen in
incomplete demyelination allowing conduction at different velocities. (CMAP) compound motor
action potential = activation of muscle fibers in a target muscle supplied by the nerve.
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Diagnostic Mimics of CIDP
Differentiating between the diagnosis of CIDP and
the alphabet soup of other immune-mediated
demyelinating neuropathies (Table #1) is difficult
due to the overlapping, and sometimes inconsistent,
set of neurologic symptoms.2,5 Guillain-Barre
syndrome (GBS) is the most frequently pursued
diagnostic option but can be differentiated best by
the time frame and course in which the symptoms
develop.5,10,12 GBS reaches its maximum severity in
a four-week monophasic course,8,15 whereas CIDP
reaches its maximum severity through either a
progressive (two-thirds of cases) or a relapsingremitting course (one-third of cases) in eight
weeks.1,4-9 Adding another layer of confusion,
treatment-related failures of GBS can mimic the
relapsing-remitting course of CIDP.15 Two atypical
variants of CIDP further complicate using the
clinical course for diagnosis. Acute CIDP (a-CIDP),
occurring in 16% of CIDP patients,15 and acute
inflammatory demyelinating polyneuropathy
(AIDP), exhibit similar symptoms, but with peak
severity closer to four weeks.4,7,8 The nature of
symptoms can also vary. GBS tends to exhibit more
severe symptoms like respiratory failure and will be
more likely to exhibit autonomic dysfunction and
cranial nerve involvement.7,12 Patients with A-CIDP,
AIDP and CIDP rarely present with these findings,
although AIDP tends to be the most severe of the
three.7,8,15 Diagnostic overlap can be seen with
electrophysiologic testing and CSF studies (Table
#2),8,9,14,15 but GBS tends to develop after infections,
especially with Campylobacter jejuni and Zika
virus.6,15
Diabetic Polyneuropathy – compounding diagnostic certainty
In this case, the diagnosis of the patient’s
longstanding neuropathy was further confounded
by the presence of diabetes, which affects 9% of
the general population and 29.6% of those people
65 years and older.6 Severe or uncontrolled cases of
diabetes can lead to diabetic peripheral neuropathy
(DPN).7 DPN, the most common peripheral
polyneuropathy, results from axonal damage due
to glycemic mediated metabolic derangement. This
glucose-mediated process is thought to disturb
neuronal metabolism, alter blood supply to the vasa
nervosum, and inflict damage to the Schwann Cells
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of the nerve sheath.2 An autoimmune response
can occur through non-enzymatic glycosylation
of myelin, whereby this glycosylation promotes
recognition and degradation by macrophages.1
While the pathology is different, DPN shares some
symptoms with CIDP, not only making it challenging
to distinguish between the two, but also masking
and augmenting symptoms of CIDP. Clues to
differentiate the two clinical pictures include DPN’s
gradual (greater than one year) progression of axonal
length-dependent symptoms, which tend to be
mostly sensory in nature and predominately affect
distal lower extremities.2
Electrophysiologic results (Table #2) and protein
levels in the CSF create further overlap due to similar
findings.2,6 Another problem with DPN is its ability to
mask concomitant CIDP as the patient concentrates
more on their pain than the change in weakness and
other neurologic symptoms.6 A combination should
be suspected in an older population, especially when
the symptoms and conduction velocities of DPN are
out of proportion for the duration of diabetes and
level of diabetic control.2,3,6 This requires a certain
level of clinical suspicion based upon comparisons
to neuropathic symptom burdens of similar patients
with only diabetes. While diagnostic criteria are less
predictive, decreasing the likelihood of treatment
initiation, treatment success rates in patients with
DPN and CIDP combined are similar to those of CIDP
alone.3,6
Importance of Rapid and Correct Diagnosis
The most important reason to correctly differentiate
a diabetic patient with concomitant CIDP from
worsening DPN is that unlike irreversible DPN, CIDP
is a treatable condition.2 The case-patient had a
prolonged course of sensory symptoms related
to DPN. Worsening neuropathic symptoms and
weakness occurred around the implantation of the
spinal cord stimulator. It is unclear how long the
patient’s CIDP was masked by his DPN. It wasn’t until
the new neurologic symptoms, initially attributed
to the stimulator, that the diagnosis was uncovered
by the subsequent neurologic evaluation. Clues for
earlier evaluation by the PCP could have been that
the patient’s sensory symptoms were refractory to
standard treatment, along with the development of
motor dysfunction and proximal weakness.
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Treatment for CIDP patients with diabetes is guided
by the treatment methodologies for CIDP alone, with
goals to decrease handicap, reduce symptoms, and
maintain long-term remission.5,7 Traditional therapy
for CIDP includes corticosteroids, plasmapheresis,
and IVIG. Improvement is seen in 50-80% of patients.5
Corticosteroid benefit is similar for progressive and
relapsing-remitting types and is effective at 60mg
daily doses of Prednisone.5 Responses are noted
as early as two months, peaking in efficacy at six
months. There is a seventy percent relapse after
discontinuation.5,6 However, because corticosteroids
can worsen glycemic control in patients with
diabetes, as well as impact osteoporosis, gastritis,
cataracts, mood changes, glaucoma and fluid
retention, IVIG and plasmapheresis are appealing
options.5 Plasmapheresis can remove up to 45% of
pathogenic humoral factors in a single exchange,
affording a 33-80% response rate.5 IVIG is usually
the preferred treatment, especially for severe cases,
and can modulate pathogenic autoantibodies,
suppress pathogenic cytokines, reduce complement
deposition, and alternate pathogenic T cell function.5
There is a 50-75% response rate within a few weeks,
which results in improved strength, functional
disability and quality of life.5 Complications for these
treatments are the expense, time consumption,
availability, and side effects ranging from headache,
rash and flu-like symptoms to volume overload,
hemolytic anemia and transient neutropenia.5
CONCLUSION
CIDP in the presence of DPN is a difficult diagnosis
for a PCP to suspect. Recognizing it from other
potential neuropathies increased the likelihood
of appropriate treatment of symptoms and
improvement in the patient’s quality of life. Early
diagnosis requires clinical suspicion. While specialist
involvement is essential, PCPs usually will be the
first to encounter this pathology and differentiate it
from the multiple mimics. PCPs should consider CIDP
superimposed on DPN when a diabetic patient has
proximal weakness and sensory symptoms refractory
to usual treatments and/or are disproportionately
greater than would be expected for the duration of
diabetes and the level of glucose control.
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